Phase I study of SAR444245 (SAR'245) as monotherapy (mono) and combined with pembrolizumab (pembro) or cetuximab (cetux) in patients (pts) with advanced solid tumors

G. S. Falchook; S. Fu; C. Lemech; M. A. Mckean; A. A. Azad; H. K. Gan; D. Sommerhalder; J. S. Wang; Tiak Ju Y. Tan; C. E. Chee; M. Barve; J. Moser; J. Mooney; N. Acuff; R. Wang; N. Marina; G. Abbadessa; M. Streit; S. Ramusovic; T. Meniawy

doi:10.1016/j.annonc.2022.07.873

Phase I study of SAR444245 (SAR'245) as monotherapy (mono) and combined with pembrolizumab (pembro) or cetuximab (cetux) in patients (pts) with advanced solid tumors

G. S. Falchook, S. Fu, C. Lemech, M. A. Mckean, A. A. Azad, H. K. Gan, D. Sommerhalder, J. S. Wang, Tiak Ju Y. Tan, C. E. Chee, M. Barve, J. Moser, J. Mooney, N. Acuff, R. Wang, N. Marina, G. Abbadessa, M. Streit, S. Ramusovic, T. Meniawy

Internal Medicine

Research output: Contribution to journal › Abstract/Meeting Abstract › peer-review

Original language	English
Pages (from-to)	S885-S886
Number of pages	2
Journal	Annals of Oncology
Volume	33
Issue number	7
DOIs	https://doi.org/10.1016/j.annonc.2022.07.873
Publication status	Published - 13 Sept 2022
Event	2022 Annual Meeting of the European-Society-for-Medical-Oncology - , France Duration: 9 Sept 2022 → 13 Sept 2022

Access to Document

10.1016/j.annonc.2022.07.873

Cite this

Falchook, G. S., Fu, S., Lemech, C., Mckean, M. A., Azad, A. A., Gan, H. K., Sommerhalder, D., Wang, J. S., Tan, T. J. Y., Chee, C. E., Barve, M., Moser, J., Mooney, J., Acuff, N., Wang, R., Marina, N., Abbadessa, G., Streit, M., Ramusovic, S., & Meniawy, T. (2022). Phase I study of SAR444245 (SAR'245) as monotherapy (mono) and combined with pembrolizumab (pembro) or cetuximab (cetux) in patients (pts) with advanced solid tumors. Annals of Oncology, 33(7), S885-S886. https://doi.org/10.1016/j.annonc.2022.07.873

@article{ca045eecca8a4841872fbd8dc3333877,

title = "Phase I study of SAR444245 (SAR'245) as monotherapy (mono) and combined with pembrolizumab (pembro) or cetuximab (cetux) in patients (pts) with advanced solid tumors",

author = "Falchook, {G. S.} and S. Fu and C. Lemech and Mckean, {M. A.} and Azad, {A. A.} and Gan, {H. K.} and D. Sommerhalder and Wang, {J. S.} and Tan, {Tiak Ju Y.} and Chee, {C. E.} and M. Barve and J. Moser and J. Mooney and N. Acuff and R. Wang and N. Marina and G. Abbadessa and M. Streit and S. Ramusovic and T. Meniawy",

year = "2022",

month = sep,

day = "13",

doi = "10.1016/j.annonc.2022.07.873",

language = "English",

volume = "33",

pages = "S885--S886",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

number = "7",

note = "2022 Annual Meeting of the European-Society-for-Medical-Oncology, ESMO 2022 ; Conference date: 09-09-2022 Through 13-09-2022",

}

Falchook, GS, Fu, S, Lemech, C, Mckean, MA, Azad, AA, Gan, HK, Sommerhalder, D, Wang, JS, Tan, TJY, Chee, CE, Barve, M, Moser, J, Mooney, J, Acuff, N, Wang, R, Marina, N, Abbadessa, G, Streit, M, Ramusovic, S & Meniawy, T 2022, 'Phase I study of SAR444245 (SAR'245) as monotherapy (mono) and combined with pembrolizumab (pembro) or cetuximab (cetux) in patients (pts) with advanced solid tumors', Annals of Oncology, vol. 33, no. 7, pp. S885-S886. https://doi.org/10.1016/j.annonc.2022.07.873

TY - JOUR

T1 - Phase I study of SAR444245 (SAR'245) as monotherapy (mono) and combined with pembrolizumab (pembro) or cetuximab (cetux) in patients (pts) with advanced solid tumors

AU - Falchook, G. S.

AU - Fu, S.

AU - Lemech, C.

AU - Mckean, M. A.

AU - Azad, A. A.

AU - Gan, H. K.

AU - Sommerhalder, D.

AU - Wang, J. S.

AU - Tan, Tiak Ju Y.

AU - Chee, C. E.

AU - Barve, M.

AU - Moser, J.

AU - Mooney, J.

AU - Acuff, N.

AU - Wang, R.

AU - Marina, N.

AU - Abbadessa, G.

AU - Streit, M.

AU - Ramusovic, S.

AU - Meniawy, T.

PY - 2022/9/13

Y1 - 2022/9/13

U2 - 10.1016/j.annonc.2022.07.873

DO - 10.1016/j.annonc.2022.07.873

M3 - Abstract/Meeting Abstract

SN - 0923-7534

VL - 33

SP - S885-S886

JO - Annals of Oncology

JF - Annals of Oncology

IS - 7

T2 - 2022 Annual Meeting of the European-Society-for-Medical-Oncology

Y2 - 9 September 2022 through 13 September 2022

ER -